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Lymphedema (LE) is a lifetime risk for breast cancer survivors. This predisposes individuals to 
infection, possibly life-threatening, leads to difficulties in clothing fit and activities of daily living, and 
also affects self-esteem, self-identity, and quality of life.Tamoxifen, considered a first-choice 
adjuvant therapy drug following breast cancer treatment, has been shown to halve the cancer 
recurrence risk. Tamoxifen is known to influence fluid and electrolyte balance with fluid retention 
(32%) being one of the most common adverse effects of the drug. Theoretically, it may act at the 
cellular level by increasing capillary membrane permeability, thus increasing the interstitial fluid 
movement and workload of a lymphatic system already compromised due to surgery and, often, 
radiation. Current literature has not reported a definitive association between tamoxifen use and LE 
occurrence.The research goal is to explore tamoxifen-related variables in LE occurrence and 
whether or not LE occurrence is higher in breast cancer survivors who take tamoxifen.A secondary 
analysis of data from an established National-Institutes-of-Health-funded parent study will be 
performed. The NIH study includes more than 200 persons newly-diagnosed with breast cancer who 
were consented, enrolled, and assessed at pre-op, post-op, and followed for 30 months. In the 
absence of a “gold standard,” the study defines four measurements of LE in exploring approaches to 
assessing and diagnosing post-breast cancer LE. In this proposal, data from a self-report of 
symptoms and tamoxifen use (≥ 6 months) are derived from the nurse interview using a validated 
measurement tool and medical record review. Data from limb volume estimation are derived from 
reliable and valid perometry measurement. 
Relationship indicators between tamoxifen and LE occurrence would provide an early identifier for 
at-risk individuals, lay groundwork for targeted interventions, and justify future research examining 
the underlying physiological cellular mechanism associated with LE emergence in the presence of 
tamoxifen. 
 
